Government funding of fluorodeoxyglucose positron emission tomography (FDG‐PET) in rare urological cancers: better data, better outcomes
BJU International · 2024
DOI: 10.1111/bju.16135 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2024. Verfasst von Jennifer Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Royal Melbourne Hospital, Parkville, Vic., Australia. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Urologic Neoplasms. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Royal Melbourne Hospital, Parkville, Vic., Australia.
- Department of Uro-Oncology, Peter MacCallum Cancer Centre, Parkville, Vic., Australia.
ORCID-Profile: Jennifer Xu, Brian Kelly, Nathan Lawrentschuk
Zitieren
APA
Xu, J., Al Saffar, H., O'Brien, J., Kelly, B., & Lawrentschuk, N. (2024). Government funding of fluorodeoxyglucose positron emission tomography (FDG‐PET) in rare urological cancers: better data, better outcomes. BJU International. https://doi.org/10.1111/bju.16135
Vancouver
Xu J, Al Saffar H, O'Brien J, Kelly B, Lawrentschuk N. Government funding of fluorodeoxyglucose positron emission tomography (FDG‐PET) in rare urological cancers: better data, better outcomes. BJU International. 2024. doi:10.1111/bju.16135
BibTeX
@article{Xu2024,
author = {Xu, Jennifer and Al Saffar, Haidar and O'Brien, Jonathan and Kelly, Brian and Lawrentschuk, Nathan},
title = {Government funding of fluorodeoxyglucose positron emission tomography (FDG‐PET) in rare urological cancers: better data, better outcomes},
journal = {BJU International},
year = {2024},
doi = {10.1111/bju.16135}
}
EUVIMED